Evidence map›Paper›PMID 38364948›Full record

ArticleInternational journal of radiation oncology, biology, physics2024

FLASH Proton Radiation Therapy Mitigates Inflammatory and Fibrotic Pathways and Preserves Cardiac Function in a Preclinical Mouse Model of Radiation-Induced Heart Disease.

Kyle Kim, Michele M Kim, Giorgos Skoufos, Eric S Diffenderfer, Seyyedeh Azar Oliaei Motlagh, Michail Kokkorakis, Ilektra Koliaki, George Morcos, Khayrullo Shoniyozov, Joanna Griffin and 8 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Reduced corneal toxicity following whole brain irradiation in mice.Clinical and translational radiation oncology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Cardiac substructure dosimetry in thoracic radiotherapy: moving beyond mean heart dose and toward precision cardiac risk mitigation.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Review
  8. Musculoskeletal and Marrow Sparing With Proton FLASH Radiation Therapy in Juvenile Mice.International journal of radiation oncology, biology, physics · 2026
    Article
  9. Article
  10. Article
  11. Microenvironmental remodeling in FLASH radiotherapy.Frontiers in cell and developmental biology · 2026
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Kyle KimDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Michele M KimDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Giorgos SkoufosDepartment of Electrical & Computer Engineering, University of Thessaly, Greece; Hellenic Pasteur Institute, Athens, Greece.
Eric S DiffenderferDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Seyyedeh Azar Oliaei MotlaghDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Michail KokkorakisDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Ilektra KoliakiDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
George MorcosDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Khayrullo ShoniyozovDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Joanna GriffinDepartment of Medicine, Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Artemis G HatzigeorgiouDepartment of Electrical & Computer Engineering, University of Thessaly, Greece; Hellenic Pasteur Institute, Athens, Greece; DIANA-Laboratory, Department of Computer Science and Biomedical Informatics, University of Thessaly, Thessaly, Greece.
James M MetzDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Alexander LinDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Steven J FeigenbergDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Keith A CengelDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Bonnie KyDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Constantinos KoumenisDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: costas.koumenis@pennmedicine.upenn.edu.
Ioannis I VerginadisDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: vioannis@pennmedicine.upenn.edu.
University of Pennsylvania · USUniversity Medical Center Groningen · NLPasteur Hellenic Institute · GRUniversity of Thessaly · GR

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL A. LAZAR · 1986 to 2026
$48.3M
Translational Studies in FLASH Particle RadiotherapyP01CA257904 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Wei Zou · 2022 to 2026
$14.2M
SUMMER UNDERGRADUATE PROGRAM TO EDUCATE RADIATION SCIENTISTS (SUPERS)R25CA140116 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JAY FITZGERALD DORSEY · 2010 to 2026
$4.1M
Mechanistic Risk Prediction of Radiation Therapy CardiotoxicityR01HL148272 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KY, BONNIE · 2020 to 2024
$3.7M
MENTORING IN PATIENT-ORIENTED RESEARCH IN DEEP PHENOTYPING IN CARDIO-ONCOLOGYK24HL167127 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Bonnie Ky · 2023 to 2026
$496k
Vevo 2100 Imaging SystemS10OD016393 · OD · UNIVERSITY OF PENNSYLVANIA · PI KAHN, MARK L · 2013 to 2013
$256k
NCATS NIH HHS UL1 TR001878NCI NIH HHS P01 CA257904NCI NIH HHS R25 CA140116NHLBI NIH HHS K24 HL167127NHLBI NIH HHS R01 HL148272NIDDK NIH HHS P30 DK019525NIH HHS S10 OD016393
6 · The paper itself

Abstract

purposeStudies during the past 9 years suggest that delivering radiation at dose rates exceeding 40 Gy/s, known as "FLASH" radiation therapy, enhances the therapeutic index of radiation therapy (RT) by decreasing normal tissue damage while maintaining tumor response compared with conventional (or standard) RT. This study demonstrates the cardioprotective benefits of FLASH proton RT (F-PRT) compared with standard (conventional) proton RT (S-PRT), as evidenced by reduced acute and chronic cardiac toxicities. METHODS AND MATERIALS: Mice were imaged using cone beam computed tomography to precisely determine the heart's apex as the beam isocenter. Irradiation was conducted using a shoot-through technique with a 5-mm diameter circular collimator. Bulk RNA-sequencing was performed on nonirradiated samples, as well as apexes treated with F-PRT or S-PRT, at 2 weeks after a single 40 Gy dose. Inflammatory responses were assessed through multiplex cytokine/chemokine microbead assay and immunofluorescence analyses. Levels of perivascular fibrosis were quantified using Masson's Trichrome and Picrosirius red staining. Additionally, cardiac tissue functionality was evaluated by 2-dimensional echocardiograms at 8- and 30-weeks post-PRT.

resultsRadiation damage was specifically localized to the heart's apex. RNA profiling of cardiac tissues treated with PRT revealed that S-PRT uniquely upregulated pathways associated with DNA damage response, induction of tumor necrosis factor superfamily, and inflammatory response, and F-PRT primarily affected cytoplasmic translation, mitochondrion organization, and adenosine triphosphate synthesis. Notably, F-PRT led to a milder inflammatory response, accompanied by significantly attenuated changes in transforming growth factor β1 and α smooth muscle actin levels. Critically, F-PRT decreased collagen deposition and better preserved cardiac functionality compared with S-PRT.

conclusionsThis study demonstrated that F-PRT reduces the induction of an inflammatory environment with lower expression of inflammatory cytokines and profibrotic factors. Importantly, the results indicate that F-PRT better preserves cardiac functionality, as confirmed by echocardiography analysis, while also mitigating the development of long-term fibrosis.

Indexed as

FibrosisHeart DiseasesInflammationProton TherapyAnimalsDisease Models, AnimalHeartMaleMiceMice, Inbred C57BLRadiation InjuriesRadiation Injuries, Experimental

Identifiers

PMID38364948
PMCPMC11209795
OpenAlexW4391848198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.